Literature DB >> 19361041

Genetic susceptibility to inflammatory injury and various adverse outcomes.

John M Murkin1, Keith R Walley.   

Abstract

For patients undergoing cardiac surgical procedures, there are multiple sources of potential end-organ injury including microgaseous and microparticulate emboli, hypoperfusion, and local and systemic inflammatory processes. These factors are independent of, but potentially synergistic with, further inherent susceptibilities resulting from patient specific co-morbidities. It is also apparent that some patients are more prone to suffer adverse outcomes than others, despite apparently similar risk profiles, giving rise to consideration of genetic susceptibilities. This review will provide a brief overview of genetic studies and the interaction between phenotype and individual patient susceptibilities with a focus on cardiac surgical procedures.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19361041      PMCID: PMC4680233     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  112 in total

1.  Low doses of activated protein C delay arterial thrombosis in rats.

Authors:  M D Smirnov; M V Pyzh; D V Borovikov; A N Atorozhilova; A B Dobrovolsky; V L Golubych; N A Gratsiansky
Journal:  Thromb Res       Date:  1990-02-15       Impact factor: 3.944

2.  Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center.

Authors:  B E Tardiff; M F Newman; A M Saunders; W J Strittmatter; J A Blumenthal; W D White; N D Croughwell; R D Davis; A D Roses; J G Reves
Journal:  Ann Thorac Surg       Date:  1997-09       Impact factor: 4.330

Review 3.  Cerestat and other NMDA antagonists in ischemic stroke.

Authors:  K R Lees
Journal:  Neurology       Date:  1997-11       Impact factor: 9.910

4.  The effect of apolipoprotein E genotype on neuron specific enolase and S-100beta levels after cardiac surgery.

Authors:  W Andrew Kofke; Patrick Konitzer; Qing Cheng Meng; Jia Guo; Albert Cheung
Journal:  Anesth Analg       Date:  2004-11       Impact factor: 5.108

5.  Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction.

Authors:  Y Gasche; M Fujimura; Y Morita-Fujimura; J C Copin; M Kawase; J Massengale; P H Chan
Journal:  J Cereb Blood Flow Metab       Date:  1999-09       Impact factor: 6.200

Review 6.  Genetics and ischaemic stroke.

Authors:  A Hassan; H S Markus
Journal:  Brain       Date:  2000-09       Impact factor: 13.501

7.  Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study.

Authors:  Dominic C Harmon; Kamran G Ghori; Nicholas P Eustace; Sheila J F O'Callaghan; Aonghus P O'Donnell; George D Shorten
Journal:  Can J Anaesth       Date:  2004-12       Impact factor: 5.063

8.  Pattern and significance of cerebral microemboli during coronary artery bypass grafting.

Authors:  S Sylivris; C Levi; G Matalanis; A Rosalion; B F Buxton; A Mitchell; G Fitt; D B Harberts; M M Saling; A M Tonkin
Journal:  Ann Thorac Surg       Date:  1998-11       Impact factor: 4.330

9.  Genetic polymorphisms of apolipoprotein E4 and tumor necrosis factor beta as predisposing factors for increased inflammatory cytokines after cardiopulmonary bypass.

Authors:  Jürg Grünenfelder; Martin Umbehr; Andre Plass; Lukas Bestmann; Friedrich E Maly; Gregor Zünd; Marko Turina
Journal:  J Thorac Cardiovasc Surg       Date:  2004-07       Impact factor: 5.209

10.  Retinal microembolism during cardiopulmonary bypass demonstrated by fluorescein angiography.

Authors:  C Blauth; J Arnold; E M Kohner; K M Taylor
Journal:  Lancet       Date:  1986-10-11       Impact factor: 79.321

View more
  1 in total

1.  An Endotoxin Tolerance Signature Predicts Sepsis and Organ Dysfunction at Initial Clinical Presentation.

Authors:  Olga M Pena; David G Hancock; Ngan H Lyle; Adam Linder; James A Russell; Jianguo Xia; Christopher D Fjell; John H Boyd; Robert E W Hancock
Journal:  EBioMedicine       Date:  2014-11-01       Impact factor: 8.143

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.